Oxford tests new shot to block malaria spread
NCT ID NCT05270265
Summary
This early-stage study tested the safety and immune response of a new vaccine designed to stop the spread of a type of malaria. It involved 25 healthy adults in the UK who received three doses of the vaccine. The main goal was to check for side effects and see if the vaccine triggered an immune response that could block malaria transmission.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA VIVAX are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CCVTM, University of Oxford, Churchill Hospital
Oxford, OX3 7LE, United Kingdom
Conditions
Explore the condition pages connected to this study.